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HIV/AIDS is a disease almost exclusively
affecting younger people, both in the pro-
ductive and reproductive times of their
lives. Antiretroviral treatment does not
cure HIV/AIDS, but effectively alters it
from a terminal to a chronic disease. As
such, ART is the most effective palliation
for HIV/AIDS so far. Given that anti-
retroviral therapy is neither freely available
nor affordable for most of the more than
90% of infected people living in sub-
Saharan Africa, HIV is a terminal disease.
This makes it a life-altering diagnosis,
impacting on the biomedical, psychosocial
and spiritual well-being of the patient.
The response to dealing with this disease
should be equally holistic, not just at the
end of life, but from the very time of diag-
nosis. Patient care from the time of diag-
nosis should be multidisciplinary, involv-
ing a diversity of practitioners. This
approach is applicable from diagnosis to
death, with close collaboration between
acute and palliative physicians.This model
of care should be encouraged because the
natural course of untreated HIV/AIDS is
characterised by a progressive deteriora-
tion of the underlying immune system,
punctuated by consequent opportunistic
infections and cancers. Progress of the
disease is also influenced by the patient's
pre-morbid immune status, previous dis-
ease, nutrition, lifestyle and social status.
FEATURES OF PALLIATIVE CARE
IN AIDS
Distinguishing characteristics of end-of-
life care in AIDS include:
• the youth of the infected person, result-
ing in more aggressive curative treat-
ment being pursued far later in the
course of the disease
• multisystem disorders with variable pre-
sentation, curable components within a
progressively fatal disease, compounding
uncertainty and creating indistinct
boundaries between cure and palliation
• a higher proportion of extremely emo-
tive issues surrounding sexuality, repro-
duction, guilt, loss of vitality, loss of
productivity and death.
BIOMEDICAL MARKERS DETER-
MINING THE TERMINAL PHASE
Clinical markers:
• cachexia
• presence of AIDS-defining diagnoses,
especially where there is no access to
HAART, or active specific treatment
with a good possibility of cure or guar-
anteed access to prophylaxis, e.g. central
nervous system (CNS) lymphoma, dis-
seminated Kaposi’s sarcoma (KS),
cytomegalovirus (CMV) viraemia 
• low rating on the Karnofsky
Performance Scale (Table I).
Laboratory markers:
• CD4 < 50 cells/µl or absolute lympho-
cyte < 0.75 × 109/l 
• high viral load.
The following are poor prognostic factors
in individual opportunistic infections, e.g.
in cryptococcal meningitis:
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Palliative care in advanced
HIV
Although antiretrovirals are the most effective
palliation for HIV, they are frequently not 
available and another approach is necessary.
Antiretroviral treatment
does not cure HIV/AIDS,
but effectively alters it
from a terminal to a
chronic disease.
MAIN TOPIC
260 C M E M a y  2 00 3   Vo l . 2 1   N o . 5
• CSF — high opening pressure,
low cell count, high antigen titre,
low glucose
• hyponatraemia
• abnormal CT scan of the brain
• extracranial evidence of crypto-
coccosis, e.g. in the lung.
Approximate survival rates for
opportunistic infections/cancers are
dependent on availability, afford-
ability and accessibility of HAART
and adjuvant active treatment:
• any AIDS-defining illness — up
to 2 years expected survival
• KS, pneumocystic pneumonia
and other opportunistic infec-
tions — median survival of 7
months
• AIDS-related cancers — median
survival of 4 months
• severe dementia — median sur-
vival 2 months
• untreated cryptococcal meningi-
tis — between 19 and 54 days.
PRACTICAL MANAGE-
MENT OF AIDS PATIENTS
This entails the formulation of
structured individualised care
plans for each patient and their
family, drawn up by the multidisci-
plinary team in conjunction with
the patient and family or care-
givers.
The multidisciplinary care team
The core of the team compri s e s :
• physicians to manage biomedical
issues — acute care physicians
for active treatment of intercur-
rent infection e.g. IV ampho-
tericin B on an in-patient basis
for patients with confirmed cryp-
tococcal meningitis; palliative
care physicians to provide symp-
tom control, e.g. analgesia and 
serial lumbar puncture to relieve
the headaches of cryptococcal
meningitis 
• social worker or psychologist to
manage psychosocial issues and
adjustment to change, e.g. loss of
income and subsequent financial
problems, assistance in complet-
ing unfinished business, e.g.
making a will, bereavement c o u n-
selling for patient and fa m i l y
• nurses for case management, to
communicate with the physician
with regard to home care issues,
monitor compliance and side-
effects of treatments, educate
caregivers about specific inter-
ventions to address biomedical
problems that may arise in the
home setting.
Adjuvant members may include:
• home care aides to assist with
activities of daily living, e.g.
bathing, to provide company, and
to call for assistance when needed
• rehabilitation specialists to assist
with specialised approaches to
reducing discomfort and increas-
ing independence, e.g. modifica-
tions to the home for non-ambu-
Definition Percentage Criteria
Able to carry out normal activity 100% Normal, no complaints, no evidence
and work, no special care of disease
needed
90% Able to carry on normal activity, minor signs
or symptoms of disease
80% Normal activity with effort, some signs or
symptoms of disease
Unable to work but able to live 70% Cares for self but unable to carry on
at home and care for most normal activity or to do active work
personal needs
Assistance needed to varying
degrees
60% Requires occasional assistance but is
able to care for most needs
50% Requires considerable assistance and
frequent medical care
Unable to care for self, requires 40% Disabled, requires special and assistance
equivalent of institutional or
hospital care, disease may be
progressing rapidly
40% Severely disabled, hospitalisation is
indicated, although death not imminent
30% Severely disabled, hospitalisation is
indicated, although death not imminent
20% Very sick, hospitalisation necessary,
active supportive treatment necessary
10% Moribund, fatal processes progressing rapidly
0 Dead
Table I. Karnofsky Performance Status Scale
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lant patients or splints to rest
acutely inflamed joints
• spiritual carers — to address
issues specific to the spirituality
of each patient (this must be
embarked upon after discussion
with and approval by the pat i e n t)





This plan must be tailored for each
patient and take into account the
community of origin with its local
practices, customs and culture.The
nursing component of the multi-
disciplinary team should facilitate
strong liaison between the spe-
cialised hospital team and the
home and hospice or palliative care
teams. The plan must address bio-
medical, psychosocial, spiritual and
cultural issues. Important steps in
the management plan include:
• assessment — collection of data,
both subjective (statements from
patient and caregivers) and
objective (detailed history, obser-
vation, examination and investi-
gations); it includes a psychoso-
cial and spiritual assessment
• problem identification or diag-
noses
• planning — setting priorities, e.g.




medium- and long-term goals of
treatment, and documented
interventions on how to achieve
those goals, preferably with time
frames 
• evaluation — an ongoing process
of assessment, to identify and
address shortfalls and achieve-
ments of the initial assessment.
CLINICAL CARE IN THE
TERMINAL PHASE
Symptoms in the terminal phase
may be due to:
• HIV itself, e.g. AIDS dementia,
HIV enteropathy, HIV neuropa-
thy
• the treatment, e.g. peripheral
neuropathy secondary to INH
(used in TB prophylaxis) or sec-
ondary to the nucleoside ana-
logues didanosine or stavudine 
• debility, e.g. odynophagia with
oropharyngeal candida, anxiety
(with/without somatic symp-
toms) secondary to fears about
mortality
• concomitant illness, e.g. dysp-
noea from pre-existing asthma.
The assessment includes a full his-
tory and relevant examination and
investigation. Many terminal
patients are inappropriately sub-
jected to aggressive invasive proce-
dures.Thus any symptom needs to
be fully assessed, keeping in mind
the following:
• premorbid performance status of
the patient
• access to effective treatment
• benefit v. possible side-effects of
treatment 
• problems with withdrawing trials
of treatment
• possible drug interactions
between new and existing drugs.
Treatment will be defined by the
cause of the symptom. Consider
the following approach:
• modification of the underlying
disease process, e.g. HAART,
nerve blocks for difficult neuro-
pathic pain
• specific drug therapy for
reversible causes, e.g. antifungals
for oesophageal candida plus sys-
temic analgesics for the
odynophagia plus antacids for
associated dyspepsia
• symptom control drug therapy
for symptoms secondary to irre-
versible causes, e.g. long-term
loperamide for diarrhoea sec-
ondary to HIV enteropathy
• non-drug therapy, e.g. relaxation
techniques for anxiety, specific
psychotherapy
• alternative therapies, e.g.
acupuncture for peripheral neu-
ropathy, music therapy as an
adjuvant for pain control
• modification of the environment,
e.g. wheelchairs for non-ambu-
lant patients, splints etc.
While it is impossible to address
control of all the possible symp-
toms in AIDS in this article, some
of the more common possibilities
are covered.
PAIN
Pain is common in AIDS and the
prevalence increases as the disease
progresses. While the principle of
assessing the cause of the pain
must be applied, it can be used in
conjunction with the WHO
stepped care strategy for pain man-
agement (Fig. 1 and Table II).
Attempts to identify the cause of
the pain should not delay the use
of analgesia.The sensitivity of the
specific pain to different analgesics,
e.g. opioids and NSAIDs, should
be kept in mind when prescribing.
Different pains should be docu-
mented, with each being given a
severity rating. Serial assessments
Pain is common in
AIDS and the preva -
lence increases as
the disease pro -
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to ascertain response to treatment
should be carried out regularly.
Treatment failure should lead to
re-assessment, to determine if the
original diagnosis was correct, if
the appropriate analgesic was cho-
sen, if the dosing amounts and fre-
quency are optimal, if adherence is
good, and if the pain is not con-
trolled because exacerbating psy-
chological elements, e.g. insomnia,
have not been addressed.The use
of co-analgesics for specific pain
management is recommended, e.g.
amitryptiline 10 - 75 mg po nocte
for the pain of peripheral neuropa-
thy or anxiolytics, e.g. lorazepam,
for pain exacerbated by anxiety.
SKIN CONDITIONS
Common skin conditions include
xeroderma, seborrhoeic dermatitis,
folliculitis, herpes zoster, and gen-
eralised pruriginous dermatitis.
Specific treatment of these condi-
tions has been addressed in other
articles, but the palliative approach
to pruritis bears mention.This
approach is in conjunction with
specific treatment dependent on
the cause.
• Try to avoid the use of electric
blankets or sitting too close to
the heater.
• Apply principles of moist wound
healing to open skin lesions, e.g.
moist compresses, saline dress-
ings, paraffin gauze.
• Add UEA or non-perfumed
bath oil to the bath water, and
avoid commercial soaps.
• Moisturise the skin with emol-
lients (UEA or aqueous cream)
after the bath.
• Cucumber used topically is a
good home remedy.
• Use weak corticosteroids in
menthol or UEA topically
• Oral antihistamines or short-
course steroids can be tried.
Pre-emptive measures to maintain
a well-moisturised, intact skin are
still the best approach. For thin
patients prone to developing pres-
sure sores, regular turning (every 2
hours), and light skin massage are
essential. Special mattresses or




Abdominal cramps with or without
diarrhoea should be assessed for
cause, but can be palliated with
antispasmodics, e.g. hyoscine
butylbromide 10 mg 8 hourly.
Nausea and vomiting should be
treated in part by treating the
underlying cause. In HIV common
causes include:
• GI infection
• GI irritation — due to toxins or
drugs




For GI causes maxolon 10 mg 6 - 8
hourly po or haloperidol 2.5 mg
stat with 0.5 - 5 mg po nocte is
useful as a first line. Raised
intracranial pressure may respond
to serial therapeutic lumbar punc-
ture for cryptococcal meningitis.
The procedure is precisely as for
the diagnostic procedure, removing
up to 10 ml of CSF at a time, until
normal CSF pressure is obtained.
Drug therapy for raised intracra-
nial pressure will often include the
addition of dexamethasone 4 - 8 m g
po daily to the first-line antiemetic.












Fig. 1. World Health Organisation 3-step analgesic ladder.








Table II. Adjuvant drugs for analgesic ladder
antiemetic that acts on the vomit-
ing centre in the brain, and con-
trols most vomiting irrespective of
the cause. Often vomiting may
need to be controlled by a combi-
nation of antiemetics, in which
case the mode of action of the cho-
sen combinations should be care-
fully researched to avoid antagonis-
tic drug interactions, e.g combin-
ing buscopan with maxolon (both
use the cholinergic pathway).
Route of administration is of prime
importance in the patient with sig-
nificant emesis, as this may pre-
clude the use of the oral route.
Rectal, subcutaneous, intravenous
and intramuscular routes can be
considered, guided by patient pref-
erence and expected duration of
treatment.
Diarrhoea may be acute, subacute
or chronic and stool microscopy
and culture is vital to ascertain the
cause. If no pathogen is isolated
and diarrhoea persists for more
than 5 days, a trial of Bactrim 2 bd
plus Flagyl 200 mg tds for 7 days
is warranted. For chronic pro-
longed or intermittent recurring
diarrhoea Mycobacterium avium,
M. tuberculosis, CMV and even KS
are possible candidates. While the
level of investigation depends on
patient preference and perfor-
mance status, as well as institution-
al protocols and budgetary con-
straints, symptomatic control of
diarrhoea is possible.The following
choices are available:
• diphenoxylate, most useful in
acute diarrhoea due to short
half-life, 10 mg po stat, with
5 mg 6 - 8 hourly thereafter 
• loperamide, useful for acute and
chronic diarrhoea, 8 mg po stat,
with 4 mg after each loose stool
(acute) or 4 - 8 mg daily in
divided doses (chronic diar-
rhoea); maximum doses of 16 -
32 mg/24 h can be used 
• codeine phosphate 30 mg qid  
• morphine po or subcutaneously
can be used as it acts both cen-
trally and peripherally, whereas
loperamide is peripheral only.
Note that diphenoxylate and lop-
eramide are more convenient,
being in tablet form. Loperamide is
also three times more potent than
diphenoxylate, and fifty times more
potent than codeine.
CONFUSION
This is a common presentation
with the CNS complications of
HIV. It is useful to differentiate
acute delirium from the more
chronic dementia. Delirium usually
implies a reversible, treatable cause
and must be investigated appropri-
ately. Fear, anxiety and decreased
level of consciousness are often
major factors, with episodes of
lucidity. Dementia is characterised,
in the later stages, by a calm, non-
aggressive patient, who has difficul-
ty retaining information. Both may
exhibit problems with memory,
concentration, orientation, halluci-
nations and delusions. It is not
unusual for an acute delirium to
compound a chronic dementia.
A full assessment to ascertain
reversible causes and to treat
appropriately is prudent, but often
in the terminal phase the cause is
multifactorial. Alcohol withdrawal,
hyperstimulation from external
stimuli, e.g. creases in sheets, dehy-
dration and psychological factors
such as anxiety are important pre-
cipitating and causative factors.
Full explanation to the family, and
the patient (if there are episodes of
lucidity) is vital. Non-drug mea-
sures include treating the patient
with dignity, avoiding restraints, re-
orientating the patient, use of a
night light, avoiding changing the
position of the patient’s bed, estab-
lishing set routines for meals and
ablutions, and having a small num-
ber of familiar staff or a close fami-
ly member involved in care.
Bringing favourite familiar items
from home to the bedside of a hos-
pitalised patient also helps.
Drug choices are guided by the
presence of hallucinations, where
an antipsychotic may be needed,
and by the need for sedation.
Choices include:
• largactil and etomine where
deep sedation is required in a
patient who is actively halluci-
nating; hypotension and arryth-
mias can be problematic with
largactil
• lorazepam 0.5 - 2 mg tds
• diazepam 2 mg 1 - 3 times daily
• midazolam  10 - 60 mg/24 h is a
useful sedative in the non-hallu-
cinating patient.
Doses must be titrated according
to need, starting at the lowest dose
and titrating up rapidly if required.
Initial studies in AIDS patients
show that extrapyramidal side-






Bereavement care for the patient
and family assists in creating an
environment conducive to a good
death. A family meeting involving
relevant family members, with or
without the patient, allows for the
transfer of information, education
of the family on the patient's con-
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Cyclizine is a good
b r o a d - s p e c t r u m
antiemetic that acts
on the vomiting
centre in the brain,
and controls most
vomiting irrespec -
tive of the cause.
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dition and for support on a practi-
cal and emotional level.These dis-
cussions should take into account
the religion and culture of the peo-
ple involved, with the health care
workers taking care not to impose
their own customs on the patient
and family.
The core multidisciplinary team of
the doctor, nurse and counsellor
(social worker or psychologist) is a
good combination to host this
meeting. Adequate time and an
appropriate venue should be
ensured.
CARING FOR THE CARERS
Caring for terminally ill patients,
especially young patients, can be a
physically, psychologically and
emotionally exhausting task.
Health care workers need to feel
confident and comfortable with
this challenge, as personal fears
and anxieties surrounding mortali-
ty are often conveyed to the
patient. Formal and informal ses-
sions with a skilled therapist to
debrief health care workers are
highly recommended, as are group
discussion and structured breaks.
CONCLUSION
AIDS has provided a challenge to
the medical fraternity at large, call-
ing for closer collaboration
between curative and palliative
care. It demands that curative
medicine adopts a higher level of
care, and that palliative medicine
adopt a reasonable measure of
cure.
IN A NUTSHELL
The natural course of untreated
HIV/AIDS is characterised by a pro-
gressive deterioration of the underly-
ing immune system, punctuated by
consequent opportunistic infections
and cancers.
ART is the most effective palliation for
HIV/AIDS so far.
Patient care from the time of diagno-
sis should be multidisciplinary.
Palliative care in AIDS is charac-
terised by a higher proportion of
extremely emotive issues surrounding
sexuality, reproduction, guilt, loss of
vitality, loss of productivity and death.
Practical management of AIDS
patients entails the formulation of
individualised care plans for each
patient and their families, drawn up
by the multidisciplinary team in con-
junction with the patient and family or
caregivers. 
Symptoms in the terminal phase may
be due to the HIV itself, treatment of
HIV or opportunistic infections, asso-
ciated debility or concomitant illness.
Clinical care involves a detailed
assessment to ascertain cause, fol-
lowed by treatment of reversible
causes, drug and non-drug palliation
of chronic symptoms, and re-evalua-
tion to assess response.
Psychosocial care is facilitated by a
family meeting involving relevant fam-
ily members, with or without the
patient, which allows for the transfer
of information, education of the family
on the patient’s condition and for
support on a practical and emotional
level.
Caring for terminally ill patients, espe-
cially young patients, can be a physi-
cally, psychologically and emotionally
exhausting task, with which health
care workers need to feel confident
and comfortable, as personal fears
and anxieties surrounding mortality
are often conveyed to the patient.
AIDS has provided a challenge to the
medical fraternity at large, calling for
closer collaboration between curative
and palliative care, demanding that
curative medicine adopts a higher
level of care, and that palliative medi-
cine adopt a reasonable measure of
cure.
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